| Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small‐molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids E Oner, M Kotmakci, AM Baird, SG Gray, B Debelec Butuner, E Bozkurt, ... Journal of Nanobiotechnology 19 (71), 1-20, 2021 | 49 | 2021 |
| Nutlin3a-loaded nanoparticles show enhanced apoptotic activity on prostate cancer cells B Debelec-Butuner, M Kotmakci, E Oner, G Ozduman, AG Kantarci Molecular Biotechnology 61, 489-497, 2019 | 11 | 2019 |
| A promising approach to develop nanostructured lipid carriers from solid lipid nanoparticles: preparation, characterization, cytotoxicity and nucleic acid binding ability E Oner, M Kotmakci, AG Kantarci Pharmaceutical Development and Technology 25 (8), 936-948, 2020 | 10 | 2020 |
| 68Ga‐labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity M Karpuz, E Ozgenc, E Oner, E Atlihan‐Gundogdu, Z Burak Drug Development Research 85 (1), e22136, 2024 | 8 | 2024 |
| Cell viability assay with 3D prostate tumor spheroids E Oner, SG Gray, SP Finn Cancer Cell Culture: Methods and Protocols, 263-275, 2023 | 5 | 2023 |
| SIRT1 siRNA-loaded lipid nanoparticles enhanced doxorubicin-induced cell death in prostate cancer cell lines B Debelec-Butuner, E Oner, M Kotmakci, AG Kantarci Journal of Drug Delivery Science and Technology 66, 102670, 2021 | 5 | 2021 |
| Nanoconjugate formulations for enhanced drug delivery E Oner, M Ilhan, HE Gultekin, M Karpuz Advanced and Modern Approaches for Drug Delivery, 441-491, 2023 | 3 | 2023 |
| A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer V M Saini, E Oner, MP Ward, S Hurley, BD Henderson, F Lewis, SP Finn, ... Molecular Oncology, 2024 | 2 | 2024 |
| Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma F Lewis, J Beirne, B Henderson, L Norris, K Cadoo, T Kelly, C Martin, ... Cancer Letters 605, 217279, 2024 | 1 | 2024 |
| Nanovesicles for intravenous drug delivery HE Gültekin, E Oner, M İlhan, M Karpuz Applications of Nanovesicular Drug Delivery, 115-148, 2022 | 1 | 2022 |
| EV275/# 415 Frequency and trends of presenting symptoms in women with ovarian cancer in a tertiary referral hospital M Kanjuga, F Lewis, M Ward, C O’Gorman, B Henderson, S Hurley, ... International Journal of Gynecological Cancer 34, A227, 2024 | | 2024 |
| EV290/# 1177 Radiological size of the pelvic mass in high-grade serous carcinomas inversely correlates with circulating tumour cell detection from the ovarian vein at surgery F Lewis, M Ward, C O’Gorman, B Henderson, S Hurley, J Beirne, ... International Journal of Gynecological Cancer 34, A233-A234, 2024 | | 2024 |
| 1342 Longitudinal detection of circulating tumour cells in serous and non-serous epithelial ovarian carcinomas F Lewis, M Ward, C O’Gorman, B Henderson, S Hurley, J Beirne, ... International Journal of Gynecological Cancer 34, A425, 2024 | | 2024 |
| Evaluation of Parsortix PR1 and PX+ Systems for the Isolation of Circulating Tumour Cells in Patients With Resectable Lung Cancer VM Saini, E Oner, S Hurley, S Nicholson, L O'Driscoll, S Finn, ... The Journal of Liquid Biopsy 1, 2023 | | 2023 |
| siRNA yüklü ilaç taşıyıcı sistem geliştirilmesi ve anti-kanser etkisinin in vitro değerlendirilmesi E Öner Marmara Üniversitesi Sağlık Bilimleri Enstitüsü, 2020 | | 2020 |
| Evaluation of the cationic solid lipid nanoparticles carrying siRNA against EphA2 receptor as non-viral delivery systems E Oner, M Kotmakci, SG Gray, AM Baird, B Debelec Butuner, AG Kantarci, ... HUMAN GENE THERAPY 30 (11), A200-A201, 2019 | | 2019 |
Gulten KantarciFarmasötik Biyoteknoloji Profesörü, Ege ÜniversitesiVerifisert e-postadresse på ege.edu.tr
